$48MSeries A, 6 May 2026
Funds back trials of KAN-001 for patients who do not respond to immune checkpoint inhibitors.
- Amount
- $48M
- Stage
- Series A
- Announced
- 6 May 2026
- Lead
- DCVC
- Other investors
- Lions Capital, Pangaea Ventures
- Use of funds
- Funds back trials of KAN-001 for patients who do not respond to immune checkpoint inhibitors.
- Checked
- Announced by the company
- Sources
- Kanvas Biosciences raises $48M Series A for microbiome cancer therapeutics pangaeaventures.com
Kanvas Biosciences raises $48M Series A for microbiome cancer therapeutics pulse2.com